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Vascular endothelial growth factor (VEGF) is an important mediator of tumor-associated angiogenesis, and con-
sequently it has been associated with metastasis. We report here that the overexpression of VEGF165 in melanoma
xenografts promotes an acceleration of tumor growth and an increase in angiogenesis as well as the spontaneous
metastasis formation. In addition, VEGF receptors (VEGFR)1, VEGFR2 and neurophilin-1 are expressed in A375
melanoma cells. Forced overexpression of VEGF in these cells induces cell growth and triggers survival activity in
serum-starved cultures, by a mechanism dependent on the mitogen-activating protein kinase signaling pathway.
Furthermore, these effects are dependent MEK 1/2 activity. Kinase domain region-specific tyrosine kinase inhib-
itors dramatically reduced DNA synthesis to 20% with respect to the controls, although they did not completely
suppress either the p44 or p42-phosphorylated forms of extracellular signal-regulated protein kinase. These in-
hibitors also provoked a decrease in Akt phosphorylation. We observed a dramatic reduction in survival after
treatment with phosphatidylinositol 30-kinase (PI3K)-specific inhibitor in the presence of specific tyrosinase in-
hibitors. We suggest that the overproduction of VEGF165 concomitantly expressed with its receptors favors cell
growth and survival of melanoma cells through MAPK and PI3K signaling pathways. These data support the involve-
ment in melanoma growth and survival of a VEGF-dependent internal autocrine loop mechanism, at least in vitro.
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Cutaneous melanoma can develop de novo either from
normal melanocytes or from precursor lesions such as
atypical dysplastic nevi or congenital nevi (Clark et al, 1984;
Herlyn et al, 1987; Albino, 1995). Using clinical and histo-
pathological criteria, the melanoma can progress from ra-
dial growth phase (RGP) lesions without competence for
metastasis to vertical growth phase (VGP), which does have
such competence (Meier et al, 1998). Despite significant
efforts to identify the genetic alterations responsible for this
progression, there are still no clear predictors for the out-
come of melanoma. To gain an insight into the cellular and
molecular pathways involved in the transition from RGP to
VGP and metastatic melanoma, we explored the role played
by the proangiogenic factor vascular endothelial growth
factor (VEGF) in this context. This approach was based on
our previous results in which we demonstrated that the mi-
crovessel densities in o1.00 mm thick melanomas were in
concordance with the aggressiveness of tumors (Marcoval
et al, 1996, 1997). Indeed, angiogenesis has been put for-
ward as a prognostic parameter in a variety of tumors such
as breast (Gasparini et al, 1997), colon (Bossi et al, 1995),
lung (Yuang et al, 1995), and prostate (Latil et al, 2000)
among others, although its value remains controversial in
melanoma (Busam et al, 1995). In melanoma, a number of
putative angiogenic factors including VEGF, basic fibroblas-
tic growth factor (bFGF), platelet-derived growth factor, IL-
8, and transforming growth factor b are expressed by me-
lanoma cells (Westphal et al, 2000). Of these factors, VEGF
is one of the most potent inducers of angiogenesis, affect-
ing endothelial cell proliferation, motility, and vascular per-
meability (Ferrara and Alitalo, 1999).
VEGF (or VEGF-A) is the founder member of a family of
growth factors, including VEGF-A, B, C, D, E, and placental
growth factor. It is a dimeric, disulfide-bonded protein with
molecular weights between Mr 25.000 and Mr 42.000. Al-
ternative splicing of the mRNA encoding VEGF generates
six different isoforms (206, 189, 183, 165, 145, 121 amino
acids) with varying heparin affinities (Robinson and Stringer,
2001). VEGF exerts its cellular functions by interacting with
two tyrosine kinase receptors, VEGFR-1 (Flt-1) and VEGFR-
2 (kinase domain region (Flk-1/KDR)), which are expressed
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almost exclusively in endothelial cells (Neufeld et al, 2001).
In addition, endothelial cells express the neuropilin-1 (NRP-
1) and NRP-2 coreceptors, which bind selectively to the 165
amino acid form of VEGF (VEGF165) (Miao and Klagsbrun,
2000). Recently, it has been reported that VEGFR-1 and
VEGFR-2 are also expressed by the tumor cells of Karposi’s
sarcoma (Masood et al, 1997), ovarian, and breast cancer
cell lines (de Jong et al, 1998), in choriocarcinoma (Char-
nock-Jones et al, 1994), and in prostate cell lines (Jackson
et al, 2002) suggesting that the physiological role of the
VEGF signaling pathway extends beyond angiogenesis in
solid tumors. Melanoma cell lines are well adapted to
growth in culture because of their low dependence on ex-
ogenous growth factors (Kath et al, 1991) but in spite of their
tumorigenicity they are not always able to develop metas-
tasis when injected into nude mice. Because of this, we
have chosen the A375P cells in which the VEGF levels are
undetectable, to study whether the forced expression of this
factor might influence the metastatic behavior by directly
evoking angiogenesis. Accordingly we set out to determine
how signaling by VEGF protein enables cells to achieve this
phenotype. As described below, overexpression of VEGF165
promotes tumor growth and metastasis without an increase
of vascular density in the primary tumor. VEGF-overex-
pressing tumors, however, accumulated slightly but con-
sistently higher hemoglobin concentration on whole-tumor
samples than controls. This new observation indicates that
VEGF165 also affects the angiogenic function. In so doing,
in serum-starved cultures we found a high level of Flk-1
tyrosine phosphorylation and we demonstrated that its
inhibition provokes an increase in apoptosis. Furthermore,
we show that VEGF165 may operate in melanoma cells as a
survival factor through phosphoinositide 3-kinase (PI3K)
activity. We thus provide evidence that VEGF signaling plays
a different role from its traditional one as a vascular inducer
and that this might contribute to the metastatic progression
of these tumors.
Results
High levels of secreted VEGF165 protein reduces the la-
tency of tumor formation and accelerates growth kinet-
ics without an increase in angiogenesis Earlier studies
have demonstrated that VEGF production is beneficial but
not required for melanoma tumorigenicity in vivo although it
does accelerate tumor expansion when overexpressed
(Graeven et al, 2001). Indeed, VEGF protein was undetect-
able in SK-Mel23, SK-Mel6, and parental A375 cells grow-
ing in vitro in which VEGF expression was only visualized by
RT-PCR. We speculate whether the overexpression of VEGF
might favor melanoma progression by tumor cell dissem-
ination through induction of new blood vessels. To test this
hypothesis, we ectopically expressed VEGF in the A375P
cell line with relatively low levels of VEGF (only detected by
RT-PCR) but able to form tumors that rarely develop me-
tastasis. Expression of transgenes was evaluated in clones
from exogenous VEGF165 in sense orientation in which the
vector was kept episomic (clone S4A-A375) or integrated
into genomic DNA (clone S7B-A375). We also included
clones with exogenous antisense VEGF165-cDNA (AS7B
and AS15A). The VEGF protein was detected in heparin-
serum-free media of cultured clones by western blot and
the amount of protein was quantified by ELISA (as shown in
Fig 1A and B, respectively).
It is important to note that all five transfected cell lines
grew in vitro at equivalent rates (without statistically signif-
icant differences) for up to 66 h in the presence of 5% fetal
calf serum (FCS) (Fig 1C). In contrast, and as expected, the
overexpression of VEGF165 resulted in a robust tumorigenic
growth in vivo with a significant reduction both in latency of
tumor formation and in growth kinetics compared with the
controls (Fig 2, panels A and B). In addition, the average size
of tumors and kinetics of growth were tremendously re-
duced in the antisense VEGF165 transfectants. At day 6 after
inoculation, the average diameter of lesions in groups that
received A375-VEGF165 cells (S4A and S7A) was increased
 4.5-fold as compared with those arising from control
neo-A375 cells, whereas those groups with AS7B cells
was o2-fold lower than those of A375P neo-1 cells (Fig 2,
panel A). All mean values of tumors achieved statistically
significant differences in comparison with controls as meas-
ured by the Mann–Whitney U test: A375P neo-1 versus
A375P S4A, p¼ 0.0177; A375P neo-1 versus A375P S7A,
p¼0.0046.
Accordingly, the differences in tumor volume doubling
time were found to be significant between the groups of
animals (A375P neo-1 vs A375P S4A (sense), p¼ 0.010; CI
95% (5.65; 23.95); A375P neo-1 vs A375P S7A (sense),
p¼0.018; CI 95% (20.46; 39.14)). In contrast, there were
no differences when comparing A375P neo-1 control group
and A375P antisense VEGF165 groups (Student’s t test). Is
important to note that in spite of the delay in tumor forma-
tion and kinetics, no spontaneous regression occurred in
the antisense VEGF165 group.
We next investigated whether the levels of VEGF165 pro-
tein affected the latency and growth of tumors by increasing
angiogenesis. On day 6 after the injection we excised very
small tumors growing in the dermis of the animals to eval-
uate vascular density. Our previous experience has taught
us that differences in vascular density should be evaluated
at a very early stage of tumor development because, once
angiogenesis is under way, new blood vessels form at
comparable rates and tumors grow to similar sizes.
The sections were stained with anti-vWF VIII antigen and
examined for numbers of intra/peritumoral vessels in 10
high power fields (  200). It is noteworthy that no sig-
nificant differences were found in vessel count between
tumors overexpressing and underexpressing VEGF (Fig 2,
panel C).
In addition, tumors harvested at days 10, 14, and 20
were assayed for hemoglobin content by Drabkin’s method.
We determined hemoglobin concentration on whole-tumor
samples and then normalized to tumor weight. Our results
show that the VEGF-overexpressing tumors accumulated
slightly but consistently higher hemoglobin concentration
on whole-tumor samples than controls at very early tumor
development. The significative differences are found at
day 14 after implantation of S4A cells into nude mice in
comparison with controls as measured by the Mann–Whitney
U test: A375P neo-1 vs A375P S4A, p¼0.019. In the an-
tisense VEGF165 tumors the hemoglobin content using
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Drabkin’s method was measurable from day 20 after im-
plantation. In contrast, the VEGF165 overexpression had no
significant effect on hemoglobin content when the weight of
tumors is 0.07 g or more. These data indicate that the ac-
celerated S4A tumorigenesis, relative to AS7B, correlates
with VEGF165 production that might enhance tumorigenesis
by promoting angiogenesis. Since no evidence of an in-
creased vessel density was observed in S4A tumors, we
suggest that VEGF165 overexpression might cause archi-
tectural and functional changes on the initiated tumor
vasculature, such as large lumina or dilation of the blood
vessels that allow the hemoglobin accumulation.
To further investigate whether low levels of VEGF165 pro-
voked the tumor cell death that caused this delay in tumor
formation or not, we analyzed apoptosis in tumors excised
15 d after inoculation. None of the tumors showed the pat-
tern of DNA-ladder characteristic of apoptotic cells (results
not shown).
These observations suggested that VEGF165 overexpres-
sion clearly benefits the early expansion of tumors by con-
tributing to angiogenesis.
Overexpression of VEGF165 confers an advantage for
metastatic development To assess potential changes in
tumor progression mediated by VEGF165 overexpression,
tumors were removed when they reached 0.4 cm3 in volume
and animals were kept alive and followed until they became
moribund or killed after 261 d. We found that differences in
tumor growth rates were maintained as described above,
between the S4A and S7B and control or antisense VEGF
transfectants. The vessel density was examined in all these
large tumors and again no differences were found between
the tumors (results not shown).
After 70–80 d, 100% of VEGF165 overexpression tumor-
bearing mice (A375P S4A cells) had developed lung me-
tastasis, as compared with only 20% of control mice. In
contrast, animals that received cells in which VEGF pro-
duction was ablated did not reveal any organ metastasis at
autopsy (Table I).
VEGF165 is a survival factor for melanoma cells through
the Flk-1/KDR, extracellular signal-regulated protein
kinase (ERK) 1/2 and PI3K signaling pathway To ac-
count for the possible autocrine effects of VEGF, we ex-
plored the expression of its receptors in melanoma cell
lines. VEGF exerts its biological functions through interac-
tion with its cognate receptors, VEGFR-1 (Flt-1) and VEG-
FR-2 (Flk-1/KDR), as well as a VEGF165-specific receptor
NRP-1 recently described (Miao et al, 2000). Using quali-
Figure1
Expression of vascular endothelial growth factor (VEGF)165 affects
the proliferation of A375 melanoma cells in vitro. (Panel A) The
histogram corresponds to the quantification of VEGF by ELISA in
serum-free conditioned media of A375P cell line or the VEGF165 trans-
fectants (clones S4A and S7A and VEGF165 clones in antisense
orientation AS7B and AS15A). Bars represent values of ELISA meas-
urements  SEM of three independent experiments. (B, top panel)
VEGF northern blot analysis of VEGF165 in A375 cells grown in vitro. (B,
middle panel) Glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
transcript as control for RNA loading. (B, bottom panel) Western blot
analysis of VEGF165 in the serum-free conditioned media of A375 cells.
Lane 1, A375P neo; lane 2, S4A; lane 3, S7A; lane 4, AS7B; and lane 5,
AS15A. (Panel C) Cell proliferation of A375 cells and the selected
clones of VEGF165 transfectants growing in vitro in the presence of 5%
fetal calf serum. The biomass was measured by SRB staining and val-
ues corresponds to the mean of absorbance (A510 nm)  SEM of three
independent experiments assayed in quadruplicate.
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tative RT-PCR, we analyzed the expression of all three
receptors in melanoma cell lines. We only observed the
expression of VEGFR in the most aggressive cell lines SK-
Mel6 and A375, which are highly tumorigenic and able to
develop metastases in immunodeficient mice. The A375 cell
line and VEGF165 transfectants growing in vitro all showed
similar levels of KDR/Flk-1, Flt-1, and NRP-1 expression
evaluated by RT-PCR (Fig 3). KDR protein was slightly in-
creased in sense VEGF165-A375 cells, suggesting an up-
regulation of this receptor as a consequence of VEGF165
overexpression (Fig 4). This observation is in agreement
with the previous reports indicating that overexpression of
VEGF led to post-transcriptional upregulation of the KDR
receptor in endothelial cells (Weisz et al, 2001).
To provide functional evidence of the role of VEGF in the
acquisition of metastatic phenotype, we investigated the
signaling pathways between VEGFR and VEGF165 in auto-
crine cell proliferation. To this purpose, we plated the cells in
the presence of 5% FCS and then switched to serum-free
media and incubated the cells for an additional 72 h. For the
last 24 h, cultures were incubated with and without specific
inhibitors of MAPK, PI3K, or exogenous VEGF165. Firstly, we
observed that all A375 cells responded to the addition of
2% FCS by increasing their DNA synthesis up to 2.2-fold
with respect to the starved cultures. In contrast, the addition
of recombinant human VEGF (rhVEGF165) had no obvious
effect on DNA synthesis (shown in Fig 5, panel A). Taken
together, these results suggested that supplementary addi-
tion of this cytokine was not necessary for cell proliferation.
In order to study the signaling pathway through VEGF165
and VEGFR-2/KDR, we incubated cells with SU 1498, a
specific inhibitor of KDR receptor phosphorylation. We
found that SU 1498 (12.8 mM) reduced the incorporation of
[methyl 3H]thymidine into all A375 cell lines by 470% with
respect to their respective baseline levels. PD 98059, a
specific inhibitor of MEK1, also reduced the DNA synthesis
up to 480% with respect to the controls. In contrast, SB
203580, a specific inhibitor of p38 MAPK, only had a mod-
erate but not significant inhibitory effect on AS7B cell pro-
liferation (Fig 5, panel A).
Previous studies have shown that the PI3K-specific in-
hibitor wortmannin is able to block the mitogenic action of
nerve growth factor and platelet-derived growth factor in
serum-deprived PC12 cells (Yao and Cooper, 1995). To ex-
plore whether PI3K was involved in the autocrine growth
pathway of VEGF/VEGFR, we incubated serum-deprived
VEGF165-A375 cells with wortmannin (30–200 nM). We ob-
served that in the presence of this inhibitor, cells appeared
as healthy and well attached to the plate as the untreated
controls. Moreover, incorporation of [methyl 3H]thymidine
into cells was not affected by wortmannin (data not shown).
Figure 2
Effect of vascular endothelial growth factor (VEGF)165 expression
on tumor growth and angiogenesis. (A–C) 106 A375 cells and
VEGF165 transfectants were injected into the dermis of BALB/c nude
mice. (A, top panel) The histogram shows the mean of lesion size ex-
pressed as volume (cm3) of tumors from eight mice at day 6 after
injection; bars, SD. (Panel B) The growth rate of i.d. tumors implanted in
nude mice. Data is presented as the mean of volume (cm3) from 10
tumors per group; bars, SE. (C, top panel) Microvessel density analysis
of tumors at day 6 after injection. The mean number of blood vessels/
field for eight individual tumors derived from each of the cell lines;
bars, SD. (D, bottom panel) Mean hemoglobin content of whole tumors
at days 10, 14, and 20; bars, SD. Statistically significant increase
(po0.05).
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In agreement with the previous reports (Gerber et al, 1998),
these results indicate that PI3K was not involved in the
proliferation of these melanoma cells.
Additionally, it was intriguing that in these previous ex-
periments, done under starvation conditions, we did not
observe a significant increase in the number of apoptotic
cells in any of the A375 cultures. We suggest that VEGF, as
well as other autocrine factors (such as bFGF or ILGF
among others), might render the cells more resistant to
apoptosis. Whether this is a consequence of increased sur-
vival activity or attributable to ongoing proliferation, or both,
remains to be determined. Thus, we focused on our pre-
vious observation of induction of cell death by KDR/VEGF
selective signaling inhibitors added to serum-starved S4A
cultures. Treatments with 12.8 mM or low concentrations of
SU 1498 maintained 80% of the cells alive for the following
48 h. To extend these observations, we incubated serum-
starved S4A cultures with 100 mM SU 1498 and they
underwent apoptotic cell death starting 18 h after the addi-
tion of the inhibitor. We consistently observed membrane
Table I. Incidence of spontaneous and experimental metastasis in vivo by A375 human melanoma cells and vascular endothelial
growth factor (VEGF)165 A375 transfectants














Id A375 P-neo 10/10 27  4 0/10 0 ND 261
A375 S4A 10/10 10  2 8/10 3–11 ND 60–72
A375 AS7B 8/8 30  5 0/8 0 ND 261
IIe A375 P-neo 5/6 3–9 0.35  0.26 75–85
A375 S4A 7/7 1–22 0.45  0.19 35–75
A375 AS7B 0/5 0 0.2  0.05 85
IIId A375 P-neo 5/5 23  3 1/5 3 0.2  0.05 200
A375 S4A 6/6 14 6/6 2–16 0.35  0.1 57–90
A375 AS7B 6/6 34  2 0/6 0 0.2  0.05 200
aThe mice were killed at the indicated days after tumor cell implantation in each experiment and pulmonary foci were examined.
bThe incidence of tumors and metastasis is expressed as the number of mice that developed tumors or lung metastatic foci/total number of inoculated
mice.
cThe data indicate the weight (g) of lungs removed when mice were sacrificed at the days indicated above.
dGroups of BALB/c nude mice were inoculated with 1  106 cells intradermally in the left flank and tumors were excised when they reach 0.4 cm3
diameter.
eGroups of BALB/c nude mice were inoculated with 1  106 cells intravenously (caudal vein tail).
Figure 3
Detection of vascular endothelial growth factor (VEGF) receptors
in human melanoma cell lines. The presence of Flt-1, neuropilin-1
(NRP-1), and kinase domain region (KDR) transcripts in neo- and
VEGF165-transfected A375 clones (S4A and AS7B), in highly invasive
Mel-6 and in non-invasive Mel 23 melanoma cell lines was analyzed by
RT-PCR (see Material and Methods). The expression of glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH) was analyzed in the same
samples as a control for loading.
Figure4
Kinase domain region (KDR) protein was detected in A375
transfectants. The expression of Flk-1/KDR protein was analyzed on
lysates from untreated cultures of A375-neo and vascular endothelial
growth factor 165-transfectant cells by western blot. The bands at the
top represent an immunoblot with an antibody specific for phosphory-
lated Flk-1 protein. The bottom panel represents an immunoblot with an
antibody for b-actin.
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blebbing, loss of contact with neighboring cells, shrinkage
of the cytoplasms, and disintegration into small vesicles (not
shown). Similar results were obtained with treatments with
SU 5614 (a different inhibitor of VEGFR tyrosine kinases),
indicating that both inhibitors provoked cell-death in a con-
centration-dependent manner. These results confirmed the
role and specificity of VEGF/KDR signals sustaining the
survival of melanoma cells under adverse culture conditions
such as serum starvation.
A convergent pathway in the mitogenic action of many
growth factors, including VEGF, is the MAPK cascade. We
found that incubation with PD 98059 induced the cell death
morphology described above. These results were corrob-
orated by the observation of a DNA ladder pattern charac-
teristic of apoptosis, which resulted from internucleosomal
cleavage of the genomic DNA, (Fig 5, panel B).
We next examined whether the MAPK cascade was in-
fluenced by the treatment of cells with SU 1498 in starved
cultures. Western blot was performed using extracts from
overexpressing VEGF165 and a specific antibody for the
activated Thr183- and Tyr185-phosphorylated form of MAPK.
Our results revealed that both p42 and p44 forms of ERK,
remained phosphorylated both in the presence and ab-
sence of SU 1498. Treatment with SU 5614 inhibitor showed
a significant reduction mainly in the phosphorylated p44
form of ERK. Neither SU 1498- nor SU 5614-specific inhib-
itors, however, completely abrogate the phosphorylation of
ERK proteins. In contrast, treatment with PD 098059 com-
pletely suppressed the phosphorylation of ERK proteins al-
though there was no significant change in the total MAP/
ERK protein (as seen by reprobing the membranes using
a specific antibody against total ERK1 and ERK2 proteins;
Fig 6). These results demonstrated that direct and selective
activation of ERK 1/2, at least in part, mediates the survival
of these melanoma cells.
Furthermore, the survival of A375 cells in our conditions
of normoxia, was not affected by wortmannin treatment
(30 nM) as assessed by the integrity of the DNA (Fig 7).
Figure 5
Different effects of specific signaling inhibitors (kinase domain re-
gion phosphorylation, MAPK, p38 MAP kinase, phosphatidylinosi-
tol 30-kinase) or exogenous vascular endothelial growth factor
(VEGF)165, on DNA synthesis and survival in cultured A375P and
VEGF165-transfected clones. (Panel A) A375P neo (white bars) and
VEGF165 transfectants (antisense VEGF165 clone 7B (hatched bars) and
sense VEGF165 clone 4A (solid bars)) were treated with the inhibitors SU
1498, PD 098059, SB 20380 as well as with 50 ng per mL recombinant
human (rh)VEGF or complete media containing 2% fetal calf serum
(FCS) (five different treatments are shown). DNA synthesis was as-
sessed by addition of 0.5 mCi per mL [methyl 3H]thymidine (see Material
and Methods). Values (c.p.m. per well) are expressed as the percentage
of controls (serum-free media containing equivalent concentration of
DMSO was considered the 100%); bars, SD. Statistically significant
increase (po0.05). Here reproducible data is shown of one of three
independent experiments assayed in triplicate. (Panel B) Agarose gel
electrophoresis of DNA fragmentation in neo- and VEGF165-transfected
A375 clones (S4A and AS7B) under serum-free media (lanes 1, 5, and 9)
or in the presence of 50 ng per mL rhVEGF (lanes 2, 6, and 10), SU 1498
(12.8 mM) (lanes 3, 7, and 11), and PD 098059 (25 mM) (lanes 4, 8, and
12). Treatments of A375P neocells are shown in lanes 1–4, the
VEGF165-antisense AS7B cells are shown in lanes 5–8 and VEGF165-
sense S4A cells are shown in lanes 9–12. On the left and right, migra-
tion of DNA size markers in the same gel is shown. The data shown is
representative of three similar and reproducible experiments.
Figure6
Effect of kinase domain region (KDR)-phosphorylation inhibition
on extracellular signal-regulated protein kinase (ERK) and Akt
activation in A375 overexpressing vascular endothelial growth
factor (VEGF)165 cultured cells. Representative western blotting with
anti-dually phosphorylated ERK 1/2 Ab (ap-ERK 1/2) or total ERK in
VEGF165-A375P-transfected cell lysates (clone S4A) exposed to KDR-
phosphorylation inhibitor SU 5416 or SU 1498 (25 mM) in comparison
with the untreated cultures. Addition of PD 098059 was included as a
control for total abrogation of the p-ERK 1/2. p-Akt was analyzed in the
same blot using a specific antibody (see Material and Methods).
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Under double treatment with Wortmannin and SU 1418
(12.8 mM) kinase inhibitor, however, cells rapidly underwent
apoptotics as shown by the DNA ladder pattern (Fig 7, lane
5). Such results indicate that a VEGF165-dependent auto-
crine survival loop may operate in melanoma cells in a PI3K
activity-dependent manner, as demonstrated by the inhib-
itory effect of the wortmannin.
Finally, we investigated whether the treatment with SU
1498 might influence the phosphorylation of Ser473-Akt or
not. Western blot using a specific antibody demonstrated
that this form, although reduced, was not completely ab-
rogated (shown in Fig 6), suggesting that the signaling
through other receptors present in such melanoma cells
may converge in this pathway.
Discussion
It has been reported that expression of VEGF correlates
with patient outcome (Straume and Akslen, 2001) and ag-
gressiveness of human melanoma xenografts (Claffey et al,
1996; Po¨tgens et al, 1996). Although these studies demon-
strated that overexpression of VEGF promotes tumor
growth, angiogenesis and metastasis in vivo, therefore,
shed no light on the mechanisms, whereby these cells ac-
quired an advantadge for progression covered up by the
belief that VEGF exclusively influenced angiogenesis. To
this effect, the expression of functional VEGFR on human
melanoma cells suggests the intriguing possibility that
VEGF might also exert autocrine effects on the tumor cells
themselves (Gitay-Goren et al, 1993; Liu et al, 1995). In-
deed, a potential autocrine role for VEGF165 and VEGFR
has been suggested for prostate cancer (Jackson et al,
2002) and angiosarcoma (Arbiser et al, 2000) as was pre-
viously described for bFGF in melanoma cell lines (Halaban
et al, 1991).
To assess an autocrine role of VEGF on melanoma cells
we developed an experimental system using stable down-
or overexpression of VEGF165 in A375 human melanoma
cells, which normally express only low baseline VEGF lev-
els. Based on our previous results showing the functional
role of Flk-1/KDR receptors in this cell line (Liu et al, 1995),
we explored whether the VEGF overexpression stimulates
tumor growth via the VEGFR-2/KDR-dependent autocrine
mechanism. Our findings in vitro provide evidence that un-
der serum-starved conditions, cell proliferation is, at least in
part, mediated by an autocrine loop involving the Flk-1/KDR
receptor and secreted VEGF165, as demonstrated by the
inhibitory effect of the specific inhibitor of VEGFR-2 recep-
tor phosphorylation SU 1498. Moreover, the activation of
ERK 1/2 was the key for DNA synthesis, as we demon-
strated by the treatment of cells with the specific inhibitor
PD 098059. These results bring us to the conclusion that
activation of ERK is required for autocrine proliferation of
these melanoma cells. Our results are consistent with re-
cent findings (Vega-Diaz et al, 2001) showing the existence
of an autocrine loop for VEGF in human dermal microvas-
cular endothelial cells. While this paper was in progress,
another study reported that the MAPK activation function-
ally contributes to the development of melanoma, as the
introduction of a constitutively active MAPKK into me-
lanocytes leads to transformation in vivo (Govindarajan et al,
2003). Furthermore, we demonstrated that the activation of
ERK 1/2 in melanoma cells also works as a survival pathway
as other authors reported in endothelial cells (Takahashi
et al, 1999; Kanno et al, 2000; Shan et al, 2004) or cortical
neurons in vitro (Ogunshola et al, 2002).
The levels of the activated Thr183 and Tyr185 (phosphory-
lated) form of MAPK were, however, not completely sup-
pressed after the treatment with either SU 1498 or SU 5614,
suggesting that other autocrine signaling converges with
the activation of the MEK-ERK pathway. Interestingly, the
exogenously added VEGF did not lead to either a significant
increase of 3H-thymidine incorporation or affect survival.
Although not studied here, this observation suggests that
the endogenous ligand produced by these cells at suffi-
ciently high levels might saturate the available binding sites
of the receptor. Similar effects of intracrine stimulation in
cells expressing a growth factor and its cognate receptors
have been described before (Valgeirsdottir et al, 1995).
Therefore, our results investigating phospho-Akt demon-
strate that disruption of the KDR pathway does not com-
pletely inhibit all VEGF165-mediated signal transduction.
This suggests that there are divergent signal transduction
pathways activated by VEGF165.
In addition to the functional VEGFR-2/KDR, we have
shown here the expression of VEGFR-1/Flt-1 and NRP-1
receptors in A375 melanoma cells. With regard to VEGFR-1/
Flt-1, our results do not support the idea that this receptor
controls the DNA synthesis of melanoma cells by activation
Figure 7
Induction of DNA fragmentation by kinase domain region (KDR)-
phosphorylation inhibition and wortmannin in A375 overexpressing
vascular endothelial growth factor (VEGF)165 in vitro. The induction
of DNA fragmentation by MAPK/extracellular signal-regulated protein
kinase inhibitor PD 098059 and SU 1498 a specific inhibitor of VEGFR-2
receptor phosphorylation was analyzed alone or in combination with
other inhibitors on serum-starved cultures of S4A cells. lane 1, un-
treated cells; lane 2, cells treated with SU 1498 (12.8 mM); lane 3, cells
treated with SU 1498 (25 mM); lane 4, cells treated with Wortmannin (30
nM); lane 5, cells treated with SU 1498 (12.8 mM) and Wortmannin (30
nM); lane 6, cells treated with PD 098059 (25 mM); lane 7, cells treated
with SB 20380 (3 mM). On the left and right are shown the migration of
DNA size markers in the same gel. The representative data of one of
three similar and reproducible experiments are shown.
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of p38. Furthermore, SB 203580, a specific inhibitor of p38
MAPK, did not abrogate the synthesis of DNA in serum-
starved A375 melanoma cells. Thus, we consider the pos-
sibility that VEGF/Flt-1 might activate p38 MAK kinase in
melanoma cells and transduce the signal for other cell
functions such as cell migration, as has been demonstrated
in endothelial cells (Kanno et al, 2000).
Little is known about the role of NRP-1 in melanoma cells
and its contribution to this autocrine loop, but it does not
appear to be a growth-signaling factor by itself (Miao et al,
2000). NRP-1 appears to function in endothelial cells as a
coreceptor that enhances the binding of VEGF165 to KDR
and its subsequent bioactivity (Bachelder et al, 2001; Soker
et al, 1998). The importance of this receptor in maintaining
breast carcinoma (Bachelder et al, 2001) or hematopoietic
stem cell survival has been recently reported (Gerber et al,
2002). In spite of the fact that such a mechanism has not yet
been elucidated, these studies suggest that NRP supports
the VEGF165 survival function in cells lacking KDR expres-
sion by stimulating the PI3K pathway. In agreement with
these findings we attribute a promoting survival role to the
PI3K contributing to the signaling elicited by KDR. This data
indicates that PI3K may prolong cell survival independently
of high-affinity receptor phosphorylation. Whether or not
NRP-1 is mediating this survival signal through PI3K re-
mains to be investigated. It is conceivable that survival
pathways mediated by NRP-1 might play a role in progres-
sion until either growth factor supply in vitro is provided, or
endogenous VEGF165 protein levels are sufficient to upreg-
ulate KDR or angiogenesis is initiated in vivo.
On the other hand, VEGF-overexpressing cells formed
rapidly expanding tumors in vivo in comparison with the
antisense cells. As in this study, earlier reports also dem-
onstrated that in vivo expansion of melanoma cells ex-
pressing VEGF antisense was delayed but not abrogated
(Graeven et al, 2001). Of note, when microvessel density
was determined at day 6 after implantation we did not find a
relationship between VEGF expression and vessel density in
these early tumors. Since bFGF (Singh et al, 1995) and an-
giopoietins (Armstrong et al, 1992; Holash et al, 1999; Si-
ddiqui et al, 2001) have been reported to be produced by
these A375 melanoma cells themselves or induced by local
host factors (Rofstad and Halsor, 2001; Li et al, 2003), we
suspect that VEGF might not represent the exclusive an-
giogenic activity in these tumors (Dvorak et al, 1995; Streit
and Detmar, 2003). Thus, we suggest that these proteins
would provide the angiogenic stimulus to initiate sprouting
angiogenesis and sustain blood vessel network in vivo,
when VEGF is downregulated. It should, however, be noted
that VEGF-overexpressing tumors accumulated slightly but
consistently higher hemoglobin concentration on whole-
tumor samples than controls at early tumor development
(o0.07 g), indicating that VEGF165 also affects the an-
giogenic function. Because microvessel densities were
comparable with controls (at least at day 6 after implanta-
tion), we suggest that VEGF165 overexpression might cause
architectural and functional changes on the co-initiated
tumor vasculature, such as large lumina or dilation of the
blood vessels (Graeven et al, 2001; Kusters et al, 2002). On
the other hand, we propose that the same causes for the
delay of tumor growth rates observed in the VEGF165-
antisense clones might also influence the growth of metas-
tasis at the secondary sites (doubly delayed by low angio-
genesis and low cell proliferation rates).
In conclusion, we report here an autocrine loop between
VEGF165 and VEGFR-2 (when both ligand and receptors
are coexpressed in the same tumor cells) that promotes, at
least in vitro, the survival and proliferation of cells under
conditions of stress or restricted growth factor supply. Tak-
en together, our results highlight that overproduction of
VEGF165 besides its angiogenic function might confer an
advantage to melanoma cells for progression through an
autocrine signaling loop.
With regard to therapy, initial attempts by using specific
inhibitors, humanized monoclonal antibodies, or by admin-
istering decoy-soluble receptors are beginning to show
promise in human cancer patients, underscoring the im-
portance of optimizing VEGF blockade (Holash et al, 2002;
Wedge et al, 2002). Until now all these efforts were de-
signed to fight tumor-induced neovascularization, but our
results suggest that blockade of VEGF165 functions in vivo,
might provide a benefit in that tumor progression might be
doubly down. These issues are currently under investigation
in our laboratory.
Material and Methods
Cell and culture conditions The human melanoma cell line
A375P (Kozlowski et al, 1984) was obtained from Dr Janet Price
(MD Anderson Cancer Center, University of Texas). SK-Mel23 and
SK-Mel6 human melanoma cell lines exhibiting low and high ag-
gressiveness in vivo (Houghton et al, 1987) were generously pro-
vided by Dr Anna Bassols (Universitat Autonoma de Barcelona,
Fac. Veterinaria, Spain). The cells were grown on plastic in an an-
tibiotic-free mixture of Dulbecco’s modified Eagle’s and Ham’s F12
(1:1 DMEM/F12) medium, supplemented with 10% (v/v) heat in-
activated fetal bovine serum, 1 mM piruvate, and 2 mM L-gluta-
mine and incubated in a humidified atmosphere of 5% CO2 in air,
subcultured twice a week after trypsinization (trypsin-EDTA). All
solutions were purchased from Life Technologies (Life Technolo-
gies Inc., Gaithersburg, Maryland). Cultures were verified to be
free of mycoplasma contamination using PCR methods (Minerva
Biolabs, Berlin, Germany).
Plasmid and gene transfer The full-length coding region of the
human VEGF165 amino acid cDNA was kindly provided by Dr Len
Seymour (CRC, Birmingham University, UK) and cloned in sense or
antisense orientation into the expression vector pRC/cytomegalo-
virus (CMV) neo (Invitrogen, San Diego, California) under the tran-
scriptional control of the CMV promoter.
For stable transfections A375P cells were seeded at a density of
1  105 to 2  105 into 35 mm dishes, and transfected with 2 mg of
DNA by Lipofectamine Reagent (Life Technologies Inc.) according
to the manufacturer’s specifications. Stable transfectants were se-
lected after 15–21 d growth in the presence of 500 mg per mL of
G418 in media. Single colonies were isolated and plated into a
2 cm2 well and then expanded.
Northern blot analysis and RT-PCR Approximately 50 mg of total
RNA were applied to a 1.1% agarose gel and electrophoresed in
the presence of 2.2 M formaldehyde as previously described
in northern blot protocols. RNA was transferred to a nylon mem-
brane (Amersham, Little Chalfont, UK) and hybridized with human
VEGF165-cDNA as a probe. Hybridization was performed at 421C
under high-stringency conditions using 32P-labeled probe (4  108
c.p.m. per mg). After hybridization with the specific probe, the
filters were stripped and rehybridyzed with glyceraldehyde-3-
1158 GRAELLS ET AL THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
phosphate dehydrogenase (GAPDH) probe, as a control for RNA
loading. Each relative RNA expression was compared with the in-
tensities of transcripts and those of GAPDH in each lane.
mRNA was obtained from cultured cell lines with a Fast-track
isolation kit (Invitrogen). Fifty nanograms of Poly (A)þ -RNA were
reverse transcribed in a total reaction volume of 20 mL. This con-
tained 1  RT buffer (50 mM Tris-HCl, pH 8.3; 75 mM KCl; and
3mM MgCl2), 20 U RNase inhibitor (Promega, Madison, Wiscon-
sin), 10 mM dithiothreitol, 50 mM deoxyribonucleoside tripho-
sphates (dNTP), 200 U Moloney murine leukemia virus reverse
transcriptase (M-MLV-RT; Life Technologies), and 0.5 mM of one
or other of the following primers: KDR-R: 50-CTTCATCAATCTT-
TACCCC-30; or random hexamers. Oligodeoxynucleotides were
purchased from Pharmacia Biotech (Genosys, Cambridge, UK).
The mixture was incubated at 371C for 60 min and 951C for
5 min, using a programmable thermal cycler (PTC-100 TM; MJ Re-
search, Watertown, Massachusetts) and stored at 801C or used
immediately.
One microliter of reaction mix was used for each PCR that in-
cluded 1 pmol of each specific primer, 200 mM each dNTP, 2 mM
MgCl2, 10 mM Tris-HCl, pH 8.3, 50 mM KCl and 1 U of Taq DNA
polymerase (Boehringer Mannheim, Mannheim, Germany). The re-
action was performed in a thermal cycler for 35 high-stringency
cycles (941C for 30 s and 651C for 45 s for high-stringency an-
nealing of primer and 721C for 45 s for extension).
The sequences of the oligonucleotides were as follows:
NRP-1 (designed from the GeneBank sequence no. AF 145712):
NP1-F: 50-AGGACAGAGACTGCAAGTATGAC-30 and NP1-R: 50-AA
CATTCAGGACCTCTC TTGA-30 (amplifies a fragment of 210 bp).
VEGFR-1/Flt-1 (designed from the GeneBank sequence no.
AF063658): Flt-1-F: 50-GTCACAGAAGAGGATGAAGGTGTC-30 and
Flt-1-R: 50-CACAGTCCGGCACGTAGGTGATT-30 (amplifies a frag-
ment of 335 bp) and VEGFR-2/KDR: KDR-F3: 50-CCTGGCG-
GCACGAAATATCCTC-30 and KDR-R4: 50-GACCAGACGTCACTG-
TGGATTG-30 (amplifies a fragment of 186 bp).
VEGF (designed from the GeneBank sequence no. AB 021221:
VEGF F: 50-TCCAGGAGTACCCTGATGAG-30 and VEGF R: 50-TCA
CCGCCTCGGCTTG TCACA-30 (amplifies a fragment of 391 bp).
GAPDH (designed from the GeneBank sequence no. AF
261085): GAPDH F: 50-CCATGGAGAAGGCTGGGG-30 and GAP-
DH R: 50-CAAAGTTGTCATGGATG ACC-30 (amplifies a fragment
of 175 bp).
Western blot hybridization Two microliters of fresh serum-free
medium containing Heparin (100 mg per mL) (Sigma Chemical Co.
St. Louis, Missouri) were incubated for 48 h with selected clones
growing in 24-well plate (TPS, Trasadingen, Switzerland). The pro-
tein concentration was determined by BCA (Pierce, Pierce Europe,
oud-Beijerland, Holland) using bovine serum albumin (BSA) as a
standard. Samples containing 50 mg of total protein were mixed
with Laemmli buffer sample, heated at 951C for 5 min before car-
rying out SDS-PAGE (Bio-Rad Mini Vertical Electrophoresis stand-
ard protocol Bio-Rad, Hercules, California) using a 12% SDS
polyacrylamide gel and then transferred to a nitrocellulose mem-
brane (Hybond ECL, Amersham Pharmacia Biotech, Buckingham-
shire, England).
Additionally, A375 cells and transfectants were treated with 12–
100 mM SU 1498 or SU 5614 (Calbiochem, La Jolla, California) in
DMSO or with DMSO alone for 24 h. Cells were lysed in lysis buffer
containing 50 mmol per liter PBS, pH 7.2, 5 mmol per liter EDTA,
5% glycerol and 0.3 mmol per liter PMSF. The protein concentra-
tion was evaluated for cell extracts and samples were elect-
rophoresed on SDS-PAGE as described above.
Membranes were blocked with blocking buffer (5% dry milk, 10
mmol per liter Tris-HCl, pH 7.5, 10 mmol per liter NaCl, 0.1%
Tween-20) and subsequently incubated with the appropriate anti-
bodies. A mouse monoclonal anti-human VEGF antibody (Santa
Cruz Biotechnology, Santa Cruz, California) was used to detect
VEGF production in conditioned media. The cell-extract mem-
branes were incubated with a phospho-VEGFR-2 polyclonal anti-
body (Cell Signaling Technologies, New England BioLabs, Beverly,
Massachussetts). p44/p42 MAPK antibody and a phosphoPlus
p44/42 MAPK antibody were used to analyze the phosphorylation
status of Erk1 and Erk2 (Cell Signaling Technologies). For detection
of the levels of Akt phosphorylation we used the PhosphoPlus Akt
(Ser 473) antibody (New England BioLabs, Beverly, Massachu-
setts). The blots were incubated first with the above antibodies and
subsequently with an anti-mouse or anti-rabbit IgG coupled
to horseradish peroxidase (Amersham Corp., Arlington Heights,
Florida) as a secondary antibody. Immunoreactive bands were
visualized by using an enhanced chemiluminiscence kit ECL
(Amersham Corp.).
Quantitation of VEGF165 by ELISA Levels of VEGF165 in condi-
tioned media of A375 cell lines were quantified by a modified col-
orimetric sandwich ELISA (R&D Systems, Minneapolis, Minnesota).
For the detection of VEGF165, individual wells of a 96-well microti-
ter plate were coated with 100 mL of a 3 mg per mL solution of an
anti-VEGF165 polyclonal antibody (AF-293-NA, R&D Systems) in 50
mM sodium carbonate buffer, pH 9.6, overnight at 41C. The wells
were then washed with PBS containing 0.03% Tween-80 and
blocked by 0.5% BSA in the same buffer for 1 h at room temper-
ature. Aliquots of diluted samples (200 mL) and VEGF165 standard
(recombinant protein 293-VE supplied by R&D Systems, ranging
from 15.6 to 1000 pg per mL) were added to each well and in-
cubated for 2 h at room temperature. The supernatant was
discarded and the wells washed. One hundred microliters of
anti-VEGF murine monoclonal antibody (MAB293, R&D Systems)
solution (1 mg per mL) was added to the microtiter plate and it was
incubated for 1 h at room temperature, after which the supernatant
was discarded and the wells were washed and incubated with
horseradish peroxidase-conjugated goat IgG specific for murine
IgG (Dakopatts, Glosrup, Denmark) at 1:250000 dilution. Finally,
the wells were developed with orthophenylenediamine (0.04%),
H2O2 in 50 mM citrate phosphate buffer, pH 5. The reaction was
stopped by 4.5 N H2SO4 and the absorbance measured at 492 nm
on a microplate reader (Titertek, Multiskan, Huntsville, Alabama).
The concentrations of VEGF165 in samples were calculated by
interpolation of a standard curve using non-linear regression anal-
ysis. Samples from two independent collections of serum-free
conditioned medium containing heparin were evaluated in two
different ELISA assays in which measurements were made in
triplicate.
Analysis of cell proliferation and DNA synthesis First we analy-
zed the cell proliferation of A375 cells and the selected clones of
VEGF165 transfectants growing in vitro in the presence of FCS. To
this purpose, 103 A375 cells were plated onto 96-well culture
plates in complete media containing 5% FCS and four wells were
harvested daily and the biomass measured by SRB staining.
To evaluate DNA synthesis under serum-free medium condi-
tions, cells were plated at a density of 2.7  105 cells per well in
media containing 2% FCS onto 24-well culture plates, cultured for
24 h and then changed to serum-free media for 72 h prior to the
addition of treatments. Medium was then replaced by fresh media
containing one of the following reagents: rhVEGF165 (50 ng per mL;
R&D Systems), PD 098059 (25 mM), an inhibitor of ERK 1/2, SU
1498 (12.8 mM), a specific inhibitor of VEGFR-2 receptor phos-
phorylation, SB 203580 (3 mM), a specific inhibitor of p38 MAPK
(Calbiochem), 30–100 nM Wortmannin, a PI3K-specific inhibitor or
2% FCS, cultured for a further 30 h. DNA synthesis was assessed
by addition of 0.5 mCi per mL [methyl 3H]thymidine (Amersham,
Buckinghamshire, UK) for the last 18 h. Incorporation of [methyl
3H]thymidine into cells was determined by liquid scintigraphy. Sta-
tistical analysis (paired sample t test) was performed using the
software SPSS (SPSS, Chicago, Illinois).
Analysis of DNA fragmentation by agarose gel elect-
rophoresis DNA was isolated from A375 and VEGF165-transfect-
ant cells growing in 10 cm Petri dishes in serum-free media with or
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without the inhibitors and rhVEGF as described above. After incu-
bation for 72 h cells were collected and then lysed using 0.6 mL
lysis solution (10 mM Tris, pH 7.5, containing 1 mM EDTA and 0.2%
Triton X-100) and treated with RNase. The protein was removed by
phenol–chloroform extraction and DNA was precipitated using
100% isopropanol and washed with 70% ethanol. Samples con-
taining equal numbers of cells were electrophoresed on a 1% ag-
arose gel in TBE buffer in parallel with DNA molecular weight
marker (123-bp DNA ladder; Life Technologies). Following elect-
rophoresis, gels were stained with ethidium bromide and photo-
graphed on a UV transilluminator.
In vivo tumorigenesis and spontaneous metastasis Athymic
BALB/c nude mice were obtained from the Animal Production
Area of Charles Rives (Lyon, France). The mice were maintained
in pathogen-free conditions and used when they were 5 weeks
old. For melanoma xenografts 1  106 cells were inoculated
intradermally (or intravenously to explore experimental metasta-
sis) in male mice. After 6 d of cell inoculation, the animals were
anesthetized and tumors dissected, harvested, and immediately
phormol included and paraffin embedded for vascular density
studies. Additionally, the growth of tumors was monitored for 40 d.
Tumor volumes were calculated from calliper measurements of
two orthogonal diameters (x and y, larger and smaller diameters,
respectively) by using the formula volume¼ xy2/2. These tumors
were excised on reaching 0.4 cm3 and the animals were kept alive
until they became moribund and then sacrificed and necropsed to
investigate the presence of spontaneous metastasis. Tumor growth
and doubling time of the volumes were compared between groups.
All procedures and animal care were carried out in accordance
with Institutional guidelines.
Mean times to reach a final target volume were compared
between the groups with Student’s t test for unpaired values. Sig-
nificant differences were determined at po0.05. The mean values
of volumes between groups were compared with the Mann–Whit-
ney U test.
Vascular density and hemoglobin measurements Vascular
counts were performed on paraffin-embedded sections of tumors
(excised 6 d after implantation) by immunostaining for Factor VIII-
related antigen (Dako, Carpenteria, California) and counterstaining
with hematoxylin. Immunochemistry was done with the avidin–
biotin–peroxidase kit with diaminobenzidine as the chromogen,
according to the instructions of the manufacturer (Vector Labs,
Burlingame, California).
Vascularity was quantified by two observers in a multiple-head-
ed microscope in six fields at  200 magnification, by selecting
areas of higher vascularization. Any positively stained vessel, end-
othelial cell or endothelial cluster that was clearly separated from
adjacent microvessels was included in the measurements (6).
The mean values of vascularity as measured by Factor VIII
staining between groups were compared with the ANOVA test.
po0.05 was considered statistically significant.
Hemoglobin content was measured on excised tumors growing
for 10, 14, and 20 d in nude mice. Whole tumors were homoge-
nized in 100 mL of double-distilled H2O using disposable pellet
pestles for microtubes. Homogenates were incubated in 500 mL of
Drabkin’s solution (Sigma Chemical Co.) for 15 min at room tem-
perature (Drabkin and Austin, 1932). Samples were centrifuged to
pellet cell debris. The absorbance was measured in the super-
natants at 540 nm. Drabkin’s solution was used as a blank.
The absorption, which is proportional to the total hemoglobin con-
centration, was normalized to tumor weight. Six tumors derived
from each of the cell lines were assayed and evaluated with the
ANOVA test.
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